进展期结肠癌术后腹腔低渗热灌注联合静脉化疗的临床研究

目的观察进展期结肠癌患者术后早期腹腔低渗热灌注（HIPEC）联合静脉化疗的临床治疗效果。方法将89例进展期结肠癌患者随机分为HIPEC联合全身化疗组44例（试验组）及单纯全身化疗组45例（对照组）。根治性结肠癌切除术后,试验组行HIPEC4次后,进行FOLFOX6静脉化疗方案。对照组则行单纯FOLFOX6化疗方案进行静脉化疗。对照观察分析两组的临床效果与预后。结果两组均无发生严重并发症。试验组KPS评分升高率为54.54%,对照组为40.00%,差异比较有统计学意义（P〈0.05） 试验组术后1、3、5年生存率分别为96.8%、72.3%、52.3%,对照组分别为95.7%、65.4%、43.0%,两组术后3、5年生存率比较,差异有统计学意义（P〈0.05）。结论HIPEC联合静脉化疗能较有效地提高结肠癌术后生存率和生存质量,是结肠癌综合治疗中较为合理的手术后辅助治疗方式。

Hyperthermic intraperitoneal chemotherapy combined with venous chemotherapy for advanced colon cancer

Objective To evaluate the clinical effects of hyperthermic intraperitoneal chemotherapy （HIPEC） combined with venous chemotherapy for the treatment of advanced colon cancer. Methods Eighty-nine cases of advanced colon cancer were randomly divided into experiment group （44 cases） and control group（45 cases）. One week after radical colonectomy, HIPEC was used four times, then the FOLFOX6 chemother- apy plan was carried out monthly for six months in experiment group. Whereas the control group was received FOLFOX6 chemotherapy plan monthly for six months only. The postoperative survival rate （1-, 3- and 5-year） and KPS scores of patients were compared between the two groups. Results There were no severe complications oe- curred in two groups. KPS scale increasing rate was 53.65% in experiment group and 40.00% in control group re- spectively（P〈O.05）. The 1-, 3- and 5-year survival rates in treatment group were 96.8%, 72.3%, 52.3% and 95.7%, 65.4%, 43.0% in control group respectively. The 3- and 5-year survival rates achieved statistical significance be- tween the two groups （P 〈0.05）. Conclusion Combined with venous chemotherapy, HIPEC can improve the prognosis and raise survival rate of the advanced colon cancer patients significantly.